Combined malonic and methylmalonic aciduria

  1. Home
  2. Wiki
This article is about CMAMMA due to ACSF3 deficiency. For CMAMMA due to malonyl-CoA decarboxylase deficiency, see malonic aciduria.
Combined malonic and methylmalonic aciduria
Other namesACSF3 deficiency, non-classic CMAMMA
SpecialtyMedical genetics
Usual onsetAll ages[1]
CausesMutations in ACSF3 gene[2]

Combined malonic and methylmalonic aciduria (CMAMMA), also called combined malonic and methylmalonic acidemia[note 1] is an inherited metabolic disease biochemically characterized by elevated levels of malonic acid and methylmalonic acid.[3] However, the methylmalonic acid levels exceed those of malonic acid.[4] CMAMMA is not only an organic aciduria but is also defined by defects of mitochondrial fatty acid synthesis (mtFAS) and mitochondrial lysine malonylation.[5][6] Researchers have suggested that CMAMMA might be one of the most common forms of methylmalonic acidemias, and possibly one of the most common inborn errors of metabolism.[2] As CMAMMA does not show up in routine newborn screening, and symptoms are variable and often appear only in adulthood, diagnoses are frequently delayed or entirely missed, making genetic methods the key to its detection.[2]

Symptoms and signs

[edit]

The clinical phenotypes of CMAMMA are highly heterogeneous and range from asymptomatic, mild to severe symptoms.[7][8] The underlying pathophysiology is not yet understood.[5] In the literature[note 2], the following symptoms have been reported:[3][4][2][9][7][10]

When the first symptoms appear in childhood, they are more likely to be intermediary metabolic disorders, whereas in adults they are usually neurological symptoms.[2]

Cause

[edit]

CMAMMA is an inborn, autosomal-recessive metabolic disorder caused by homozygous or compound heterozygous variants in the ACSF3 gene.[2] This results in a defect of the mitochondrial enzyme acyl-CoA synthetase family member 3 (ACSF3), leading to reduced or complete loss of its activity.[2] The ACSF3 gene, located on chromosome 16 at locus q24.3, consists of 14 exons and produces four alternatively spliced mRNAs that encode two isoforms of the ACSF3 protein:

  • a 576-amino-acid protein (isoform 1) and
  • a shorter 311-amino-acid protein (isoform 2), which begins translation at a downstream start codon relative to isoform 1.[12][13]

Based on minor allele frequency (MAF), a prevalence of ~ 1: 30 000 can be predicted for CMAMMA.[2]

Pathophysiology

[edit]
Schematic overview of the pathophysiology of CMAMMA.

ACSF3 encodes an acyl-CoA synthetase, which is localized in the mitochondrial matrix and has a high specificity for malonic acid and methylmalonic acid.[14][15] These substrates are activated by ACSF3 through an ATP-dependent reaction, linking them to coenzyme A (CoA) and generating the thioesters malonyl-CoA and methylmalonyl-CoA.[2] The corresponding biochemical reactions are in vivo as follows:

ATP + malonate + CoA → AMP + diphosphate + malonyl-CoA
ATP + methylmalonate + CoA → AMP + diphosphate + methylmalonyl-CoA

ACSF3, whose activity also depends on magnesium (Mg2+), most efficiently converts malonate and activates methylmalonate at about 70% of that rate.[14] Lignoceric acid (C24) has been reported as an additional substrate, although in vitro studies provide conflicting results.[16][14]

Primary effects

[edit]

Based on the ACSF3-catalyzed reactions described above, the following subsections outline the metabolic consequences of CMAMMA, beginning with the accumulation of the upstream substrates malonate and methylmalonate, and followed by deficiencies of the downstream products malonyl-CoA and methylmalonyl-CoA:

Substrate accumulations

[edit]

The defect in ACSF3 results in impaired detoxification, as malonic acid and methylmalonic acid are not converted into their CoA derivatives and therefore these substrates accumulate.[6]

Malonic acid
[edit]

The exact mitochondrial origin of malonic acid is unknown, but its transport properties are partly understood: it crosses plasma membranes only to a limited extent, with uptake increasing under acidic conditions, and within cells it enters mitochondria via the dicarboxylate carrier SLC25A10 that also transports succinate, malate, and oxaloacetate.[14][17] A major proposed source is the non-enzymatic hydrolysis of cytosolic malonyl-CoA generated during de novo fatty acid synthesis, whose levels correlate with lipogenic activity.[15] Enzymatic hydrolysis by acyl-CoA thioesterases may also contribute, alongside other potential routes such as slow carboxylation of acetyl-CoA by propionyl-CoA carboxylase, decarboxylation of oxaloacetate, oxidation of malondialdehyde, and conversion of β-alanine via malonate semialdehyde.[15] Beyond endogenous formation, exogenous sources may also contribute from the diet, with free malonic acid occurring in plants such as legumes.[14]

Malonic acid is an antimetabolite that acts as a classic competitive inhibitor of succinate dehydrogenase (Complex II) in the mitochondrial electron transport chain, thereby blocking succinate oxidation and impairing the citric acid cycle.[15] This inhibition reduces mitochondrial respiration and can be cytotoxic, particularly in cells with high oxidative metabolism such as striatal neurons.[6][15]

Methylmalonic acid
[edit]
Propionate metabolism pathway in mitochondria, with methylmalonic acid as a by-product and the role of ACSF3 in its degradation

Methylmalonic acid accumulates to even higher levels than malonic acid, making it the biochemical hallmark of CMAMMA and places it among the methylmalonic acidemias.

The origin of methylmalonic acid is the propionate metabolism pathway in mitochondria, in which the essential amino acids valine, threonine, methionine, and isoleucine, odd-chained fatty acids, propionic acid and the cholesterol side chain are converted into propionyl-CoA.[18] Propionic acid arises from bacterial fermentation in the gut and from dietary intake, being naturally present in certain cheeses or added as a preservative, especially in baked goods.[19] Propionyl-CoA carboxylase forms D-methylmalonyl-CoA, which is epimerized to L-methylmalonyl-CoA and converted by methylmalonyl-CoA mutase to succinyl-CoA for entry into the citric acid cycle, a reaction that requires the coenzyme adenosylcobalamin.[20] However, D-methylmalonyl-CoA may also be hydrolyzed by D-methylmalonyl-CoA hydrolase, releasing coenzyme A and generating methylmalonic acid, which represents a by-product of this pathway.[20] The more unspecific mitochondrial acyl-CoA thioesterase 9 (ACOT9) can likewise hydrolyze methylmalonyl-CoA, irrespective of isomer, to methylmalonic acid, with the enzyme’s activity being strongly regulated by NADH and free CoA.[21]

But in CMAMMA, methylmalonic acid mainly derives from threonine metabolism, as shown in Acsf3 knockout mice.[22]

In vitro, a connection between free methylmalonic acid and neurotoxicity has been established.[23]

Product deficiencies

[edit]

In addition to substrate accumulation, the defective ACSF3 also results in reduced levels of the mitochondrial products malonyl-CoA and methylmalonyl-CoA.

Malonyl-CoA
[edit]

Malonyl-CoA is a membrane-impermeable intermediate that requires local synthesis within mitochondria.[14] Although the exact origin of mitochondrial malonyl-CoA remains debated, the pool is thought to be provided by ACSF3 from malonic acid and by the mitochondrial isoform of acetyl-CoA carboxylase 1 (mtACC1) from acetyl-CoA.[24][25] Partial compensation of defective ACSF3 by mtACC1 could explain the broad clinical heterogeneity of CMAMMA.[26] Mitochondrial malonyl-CoA is required for mitochondrial fatty acid synthesis, lysine malonylation, acetyl-CoA synthesis and incorporation into cellular lipids.[5][6]

Mitochondrial fatty acid synthesis
[edit]
Mitochondrial fatty acid synthesis pathway with malonyl-CoA as a key intermediate and the role of ACSF3 in its synthesis.

Mitochondrial fatty acid synthesis (mtFAS) has been described as a nutrient-responsive signaling pathway linked to acetyl-CoA utilization, respiratory chain function, iron–sulfur cluster biogenesis, mitochondrial translation, and llipid-mediated signaling processes.[24][5] In this pathway, malonyl-CoA serves as the precursor of the chain extender unit malonyl-ACP (C3), which, in a condensation reaction with CO2 release, elongates the ACP-bound fatty acid chain by two carbons per round.[14][27] It generates acyl-ACP species of different chain lengths, which fulfill distinct functions:

Octanoyl-ACP (C8) is one such mtFAS product and the direct precursor of lipoic acid, which serves as a cofactor for several mitochondrial enzymes in energy metabolism.[28] In fibroblasts from CMAMMA patients, lower concentrations of octanoyl-carnitine were observed, suggesting impaired mtFAS with reduced octanoyl-ACP availability, consistent with decreased lipoylation of the α-ketoglutarate dehydrogenase complex (α-KGDH) in all cases and the pyruvate dehydrogenase complex (PDH) in some but not all cases.[5] The overall effect of impaired mtFAS on protein lipoylation is likely underestimated, as other lipoylated mitochondrial multienzyme complexes, including the 2-oxoadipate dehydrogenase complex, the branched-chain α-keto acid dehydrogenase complex, and the glycine cleavage system, were not examined.[5]

In contrast, longer-chain acyl-ACP species (C10–16) allosterically activate the network of LYRM proteins.[29][30] In humans, this network comprises at least 12 proteins and regulates mitochondrial translation, iron–sulfur cluster biogenesis, and the assembly of electron transport chain complexes.[31][30]

Lysine malonylation
[edit]

Lysine malonylation is a dynamically regulated post-translational modification in which malonyl groups are added to lysine residues of proteins, reversing their positive charge into a negative one and increasing their steric bulk.[32] This can influence protein conformation, enzyme activity, and protein–protein interactions and has been linked to the regulation of energy metabolism, in particular glycolysis and β-oxidation.[33] ACSF3 expression, tightly coupled to feeding cycles, controls the extent of mitochondrial lysine malonylation by regulating the availability of malonyl-CoA, which serves as the donor of malonyl groups.[34]

In ACSF3 and Acsf3 knockout models, mitochondrial protein malonylation was shown to be markedly reduced, confirming that ACSF3-derived malonyl-CoA is required for this modification.[6][34] It has been proposed that reduction in lysine malonylation contributes more than malonic acid accumulation to the widespread mitochondrial dysfunction observed in CMAMMA.[35]

Acetyl-CoA synthesis
[edit]

Malonyl-CoA can also be converted to acetyl-CoA by malonyl-CoA decarboxylase (MCD), providing a minor additional pathway of acetyl-CoA synthesis for oxidation in the citric acid cycle.[15] When ACSF3 is defective, mitochondrial malonyl-CoA is reduced, which may impair the supplementary pathway from malonic acid to acetyl-CoA via malonyl-CoA.[15] The clinical similarity between CMAMMA and malonic aciduria supports the view that ACSF3 and MCD act within the same pathway.[15]

Incorporation into cellular lipids
[edit]

ACSF3-derived malonyl-CoA is required for lipid synthesis, as shown by the reduced incorporation of malonate into cellular lipids in ACSF3-knockout HEK293 cells.[6]

Methylmalonyl-CoA
[edit]

Alongside malonyl-CoA, methylmalonyl-CoA is also a product of ACSF3 and likewise cannot cross biological membranes by passive diffusion.[7][36] The mitochondrial methylmalonyl-CoA pool, however, is primarily provided via the propionate metabolism pathway, where it is synthesized from propionyl-CoA by propionyl-CoA carboxylase.[20] Methylmalonyl-CoA functions as direct precursor of mitochondrial succinyl-CoA through its conversion by methylmalonyl-CoA mutase, thereby supporting anaplerotic replenishment of citric acid cycle (TCA cyle) intermediates.[37] The importance of this anaplerosis varies with tissue type and metabolite levels and is particularly pronounced in the brain, where maintaining the α-ketoglutarate pool supports the production of GABA and glutamine.[37] Mitochondrial succinyl-CoA is also essential for substrate-level phosphorylation in the TCA cycle, heme biosynthesis, ketone body utilization, and lysine succinylation.[38]

In CMAMMA, methylmalonyl-CoA does not accumulate, a major distinction from isolated methylmalonic acidemias, suggesting that their acute metabolic symptoms may be driven by methylmalonyl-CoA rather than by methylmalonic acid.[39] In line with this, the pathological post-translational modification lysine methylmalonylation, for which methylmalonyl-CoA serves as the donor, is reduced in Acsf3 knockout mice and is even lower than in healthy controls.[39]

Secondary effects

[edit]

Beyond the primary effects, fibroblasts from CMAMMA patients show reduced metabolic flexibility, which is the ability to upregulate alternative pathways for energy production.[5] This is reflected in reduced glycolytic flux and spare respiratory capacity (SRC)—the difference between maximal and basal mitochondrial respiration—and in an increased reliance on β-oxidation for energy production.[5] It is accompanied by reduced concentrations of anaplerotic amino acids such as aspartate, glutamine, isoleucine, threonine and leucine, which also contribute to sustaining basal respiration.[5]

In addition, CMAMMA fibroblasts show altered mitochondrial dynamics—the balance between fusion and fission—suggesting a secondary mechanism to cope with the metabolic dysregulation.[28] This is reflected in reduced levels of the fusion mediators mitofusin-1 (MFN1) and mitofusin-2 (MFN2) and abnormal phosphorylation of the fission mediator dynamin-related protein 1 (DRP1), resulting in mitochondria that are smaller, more numerous, and fragmented rather than elongated.[28] Mitochondrial fragmentation increases fatty acid oxidation by reducing the sensitivity of carnitine palmitoyltransferase 1 (CPT1) to malonyl-CoA, thereby influencing cellular substrate preference and capacity, but fragmentation also enables the segregation of dysfunctional mitochondria for removal by mitophagy.[40][41] As in other diseases with disturbed mitochondrial dynamics, CMAMMA is also associated with alterations of the endosomal–lysosomal system, reflected by an overrepresentation of proteins in the endosomal (15-fold) and lysosomal lumen (10-fold).[28]

CMAMMA fibroblasts are also associated with disturbances of lipid homeostasis, affecting membrane composition and in particular lipid-mediated signaling.[5] Ceramides are reduced, while sphingomyelin—a plasma membrane component that contributes to the efficiency of signal transduction—is proportionally increased, indicating reduced sphingomyelinase activity.[5] Cardiolipins, localized in the inner mitochondrial membrane where they regulate mitochondrial dynamics and apoptosis as well as stabilize respiratory chain complexes and supercomplexes, show an altered profile with greater unsaturation and unusually long species.[42][5] Their increased levels are consistent with the reduced mitochondrial spare respiratory capacity and may reflect the compensatory up-regulation of Complex IV.[5] Beyond these bioactive lipids, structural membrane lipids are also altered, with phosphatidylglycerins decreased as precursors of cardiolipin synthesis, phosphatidylcholines reduced as major components of cellular membranes, and triacylglycerides, the main storage lipids, are increased about two-fold with altered chain length and odd-chain species arising from propionyl-CoA, accompanied by increased expression of CD36.[5]

Tertiary effects

[edit]

Patients with CMAMMA often develop neurological symptoms later in life, including seizures, psychiatric problems, memory impairment, and progressive cognitive decline.[26] These tertiary effects suggest a link between disturbed energy metabolism and neurodegeneration.[26] Although neural cells have a high energy demand, they cannot efficiently rely on fatty acids for energy, with the exception of certain hypothalamic neurons and astrocytes.[26] In CMAMMA, a fibroblast study demonstrated a compensatory shift toward mitochondrial β-oxidation, a process associated with higher oxygen consumption, hypoxia, and oxidative stress.[26] It is therefore hypothesized that chronic reliance on β-oxidation in neural tissue, together with dysregulated mitochondrial dynamics and impaired lysosomal clearance of misfolded proteins or toxic products, may drive the gradual progression toward neurodegeneration observed in these patients.[26][28]

Diagnosis

[edit]

CMAMMA is thought to be an under-recognized disorder, as it escapes detection by newborn screening programs and presents with a wide range of clinical symptoms.[3][4] In many case reports, severe or recurrent infections were the trigger for seeking medical attention, which, after further investigations, led to the diagnosis of CMAMMA.[3][7][10][11]

Newborn screening programs

[edit]

Newborn screenings detect possible methylmalonic acidemias in first-tier testing by elevated propionylcarnitine (C3) and abnormal ratios such as propionylcarnitine to acetylcarnitine (C3/C2) or C3/methionine in dried blood spots.[43][44][45] However, methylmalonic acid is measured only in later-tier testing after abnormal first-tier markers, and CMAMMA is not detected by this approach because propionylcarnitine remains normal.[43][44][45][3]

Routine and biochemical labs

[edit]

Biochemically, CMAMMA is characterized by methylmalonic acid levels exceeding those of malonic acid and for differential diagnosis, it can be rapidly distinguished from classic methylmalonic acidemias by the blood plasma methylmalonic acid to malonic acid ratio.[3]

The following table summarizes reported blood and urine values[note 3] of methylmalonic acid, malonic acid, and their ratio in CMAMMA patients:

Blood plasma or serum (µmol/L) Reference range

(µmol/L)

Analytical method Urine (mmol/mol Cr) Reference range

(mmol/mol Cr)

Analytical method Note
Methylmalonic acid (MMA) 5-50 [2] < 0.4 [2] LC-MS/MS[2] 90-230[2] < 3[2] GC/MS[2] Considerably lower than in methylmalonic acidemias of the types mut0, mut-, cblA, cblB and cblDv2.[46] Vitamin B12 supplementation has no significant effect on methylmalonic acid levels.[4]
Malonic acid (MA) 2-10 [2][6] < 0.9 [2] GC/MS[2] 15-70 µm[2][6] Below detection[2] GC/MS[2] Urinary malonic acid is not a suitable marker, as it is often missed in routine analysis due to co-elution with methylmalonic acid and low excretion levels.[3]
MMA/MA ratio 2-6[2] Not defined[3] UPLC-MS/MS[3] Not suitable for ratio calculation[3] Clear differentiation from other methylmalonic acidemias requires measuring the ratio in blood plasma instead of urine.[3] A ratio below 1 indicates malonic aciduria.[47]

In CMAMMA, the acylcarnitine profile is normal, including propionylcarnitine (C3), as malonyl-CoA, propionyl-CoA, and methylmalonyl-CoA do not accumulate, and homocysteine, vitamin B12, and ammonia are also within the normal range in the absence of other disorders.[4][8]

Molecular genetic testing

[edit]

Genomic techniques represent a key diagnostic tool for CMAMMA, especially when early biochemical detection has been missed.[2] The final diagnosis is defined by biallelic pathogenic variants in the ACSF3 gene, which can be identified on the one hand, through targeted testing usually prompted by elevated methylmalonic acid levels and detected using specific multigene panels for methylmalonic acidemias.[46][48] On the other hand, CMAMMA may be discovered incidentally during broader genetic investigations for unexplained clinical features.

Expanded carrier screening (ECS) in the context of fertility treatment can detect heterozygous ACSF3 variants, which are asymptomatic in carriers but indicate a reproductive risk when both partners are carriers.[49]

Treatments

[edit]

Currently, no treatment has been conclusively shown to be effective in managing CMAMMA.[10] The following treatment options are under discussion:

Dietary interventions

[edit]

Diet interventions have been proposed to reduce the accumulation of malonic acid and methylmalonic acid, although results have been conflicting.[47][8] While a 1998 case report, describing a CMAMMA patient with normal malonyl-CoA decarboxylase activity but without genetic testing for ACSF3, recommended a high-carbohydrate, low-protein diet, a later study reported no influence of protein restriction on methylmalonic acid levels.[47][8]

Vitamin B12

[edit]

Since some methylmalonic acidemias respond to vitamin B12, treatment attempts in CMAMMA with vitamin B12 have been made, also in the form of hydroxocobalamin injections, which, however did not lead to any clinical or biochemical effects.[4]

L-Carnitine

[edit]

L-Carnitine facilitates the excretion of acyl-CoA esters by converting them into acylcarnitines via carnitine acyltransferases, but in CMAMMA such CoA esters do not accumulate as in isolated methylmalonic acidemias, and carnitine acyltransferases cannot utilize malonic or methylmalonic acid as substrates.[50][39] One study mentions treatment with L-carnitine in patients with CMAMMA, but only retrospectively and without mentioning results.[4]

mRNA therapy

[edit]

Preclinical proof of concept studies in animal models have shown that mRNA therapy is also suitable for use in rare metabolic diseases.[51] In this context, Moderna’s therapy candidate mRNA-3705 for mut-type methylmalonic acidemia, currently in phase 1/2, is notable.[52] While it is not targeted at CMAMMA, it illustrates the potential of such approaches for similar metabolic disorders.

Research

[edit]

Timeline

[edit]

In 1984, CMAMMA due to malonyl-CoA decarboxylase deficiency[note 4] was described for the first time in a scientific literature, today known as malonic aciduria.[55][47] A decade later, the first cases of CMAMMA with normal malonyl-CoA decarboxylase activity were reported in 1994 and 1998; however, the 1994 case showed an ACSF3-atypical pattern of higher levels of malonic acid than methylmalonic acid, and in the absence of genetic data the involvement of ACSF3 in both cases remains uncertain.[56][47] In 2011, genetic research through exome sequencing identified the ACSF3 gene as cause of CMAMMA with normal malonyl-CoA decarboxylase, simultaneously representing the first described human disorder in the acyl-CoA synthetase family.[2] A study published in 2016, showed that calculating the malonic acid/methylmalonic acid ratio in blood plasma offers a rapid, metabolic method for diagnosing CMAMMA.[3]

Québec cohort

[edit]

The Quebec Neonatal Blood and Urine Screening Program made Quebec province interesting for CMAMMA research, as it provided the only patient cohort in the world without selection bias.[4] Between 1975 and 2010, an estimated 2,695,000 newborns were screened, with 3 detections of CMAMMA.[8] However, based on this lower detection rate to the predicted rate by heterozygous frequencies, it is likely that not all newborns with this biochemical phenotype were detected by the screening program.[8] A 2019 study subsequently reported 25 CMAMMA patients in the province of Quebec, all but one of whom came to clinical attention through the Provincial Neonatal Urine Screening Program—20 directly and four after the diagnosis of an older sibling.[4] The urine component of the neonatal screening program was discontinued in April 2025.[57]

Phenotypic series

[edit]

The following diseases also have biochemically elevated levels of malonic acid and methylmalonic acid:

See also

[edit]

Notes

[edit]
  1. ^ The term combined malonic and methylmalonic aciduria with the suffix -uria (from Greek ouron, urine) has become established in the scientific literature in contrast to the other term combined malonic and methylmalonic acidemia with the suffix -emia (from Greek aima, blood). However, in the context of CMAMMA, no clear distinction is made, since malonic acid and methylmalonic acid are elevated in both blood and urine.
  2. ^ Literature on cases of CMAMMA with normal malonyl-CoA decarboxylase activity without confirmation of ACSF3 gene variants was not considered.
  3. ^ Clinically rounded values
  4. ^ In CMAMMA due to malonyl-CoA decarboxylase deficiency, both malonic acid and methylmalonic acid are elevated, which led to the disorder initially being referred to as combined malonic and methylmalonic aciduria. Although ACSF3 deficiency was not discovered until later, the term combined malonic and methylmalonic aciduria has now become established in medical databases for ACSF3 deficiency.[53][54]

References

[edit]
  1. ^ "Combined malonic and methylmalonic acidemia". Orphanet. Retrieved 2025-09-08.
  2. ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah ai aj ak al am an ao NIH Intramural Sequencing Center Group; Sloan, Jennifer L; Johnston, Jennifer J; Manoli, Irini; Chandler, Randy J; Krause, Caitlin; Carrillo-Carrasco, Nuria; Chandrasekaran, Suma D; Sysol, Justin R; O'Brien, Kevin; Hauser, Natalie S (2011). "Exome sequencing identifies ACSF3 as a cause of combined malonic and methylmalonic aciduria". Nature Genetics. 43 (9): 883–886. doi:10.1038/ng.908. ISSN 1061-4036. PMC 3163731. PMID 21841779.
  3. ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa De Sain-Van Der Velden, Monique G. M.; Van Der Ham, Maria; Jans, Judith J.; Visser, Gepke; Prinsen, Hubertus C. M. T.; Verhoeven-Duif, Nanda M.; Van Gassen, Koen L. I.; Van Hasselt, Peter M. (2016). "A New Approach for Fast Metabolic Diagnostics in CMAMMA". JIMD Reports, Volume 30. Vol. 30. pp. 15–22. doi:10.1007/8904_2016_531. ISBN 978-3-662-53680-3. PMC 5110436. PMID 26915364. {{cite book}}: |journal= ignored (help)
  4. ^ a b c d e f g h i j k l m n o Levtova, Alina; Waters, Paula J.; Buhas, Daniela; Lévesque, Sébastien; Auray-Blais, Christiane; Clarke, Joe T.R.; Laframboise, Rachel; Maranda, Bruno; Mitchell, Grant A.; Brunel-Guitton, Catherine; Braverman, Nancy E. (2019). "Combined malonic and methylmalonic aciduria due to ACSF3 mutations: Benign clinical course in an unselected cohort". Journal of Inherited Metabolic Disease. 42 (1): 107–116. doi:10.1002/jimd.12032. ISSN 0141-8955. PMID 30740739. S2CID 73436689.
  5. ^ a b c d e f g h i j k l m n Wehbe, Zeinab; Behringer, Sidney; Alatibi, Khaled; Watkins, David; Rosenblatt, David; Spiekerkoetter, Ute; Tucci, Sara (2019). "The emerging role of the mitochondrial fatty-acid synthase (mtFASII) in the regulation of energy metabolism". Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1864 (11): 1629–1643. doi:10.1016/j.bbalip.2019.07.012. PMID 31376476. S2CID 199404906.
  6. ^ a b c d e f g h Bowman, Caitlyn E.; Rodriguez, Susana; Selen Alpergin, Ebru S.; Acoba, Michelle G.; Zhao, Liang; Hartung, Thomas; Claypool, Steven M.; Watkins, Paul A.; Wolfgang, Michael J. (2017). "The Mammalian Malonyl-CoA Synthetase ACSF3 Is Required for Mitochondrial Protein Malonylation and Metabolic Efficiency". Cell Chemical Biology. 24 (6): 673–684.e4. doi:10.1016/j.chembiol.2017.04.009. ISSN 2451-9456. PMC 5482780. PMID 28479296.
  7. ^ a b c d e f Wang, Ping; Shu, Jianbo; Gu, Chunyu; Yu, Xiaoli; Zheng, Jie; Zhang, Chunhua; Cai, Chunquan (2021). "Combined Malonic and Methylmalonic Aciduria Due to ACSF3 Variants Results in Benign Clinical Course in Three Chinese Patients". Frontiers in Pediatrics. 9 751895. doi:10.3389/fped.2021.751895. ISSN 2296-2360. PMC 8658908. PMID 34900860.
  8. ^ a b c d e f Alfares, A.; Nunez, L. D.; Al-Thihli, K.; Mitchell, J.; Melancon, S.; Anastasio, N.; Ha, K. C. H.; Majewski, J.; Rosenblatt, D. S.; Braverman, N. (2011). "Combined malonic and methylmalonic aciduria: exome sequencing reveals mutations in the ACSF3 gene in patients with a non-classic phenotype". Journal of Medical Genetics. 48 (9): 602–605. doi:10.1136/jmedgenet-2011-100230. ISSN 0022-2593. PMID 21785126. S2CID 19352176.
  9. ^ a b c d e Pupavac, Mihaela; Tian, Xia; Chu, Jordan; Wang, Guoli; Feng, Yanming; Chen, Stella; Fenter, Remington; Zhang, Victor W.; Wang, Jing; Watkins, David; Wong, Lee-Jun; Rosenblatt, David S. (March 2016). "Added value of next generation gene panel analysis for patients with elevated methylmalonic acid and no clinical diagnosis following functional studies of vitamin B12 metabolism". Molecular Genetics and Metabolism. 117 (3): 363–368. doi:10.1016/j.ymgme.2016.01.008.
  10. ^ a b c d Lee, Joon Kee; Oh, Arum (2023). "Combined Malonic and Methylmalonic Aciduria Diagnosed by Recurrent and Severe Infections Mimicking a Primary Immunodeficiency Disease: A Case Report". Journal of Korean Medical Science. 38 (45) e387. doi:10.3346/jkms.2023.38.e387. ISSN 1011-8934. PMC 10659923. PMID 37987109.
  11. ^ a b Fathi, Mohadeseh; Khalilian, Sheyda; Miryounesi, Mohammad; Ghafouri-Fard, Soudeh (2025-05-12). "Spectrum of genetic mutations in methylmalonic aciduria among Iranian patients". Scientific Reports. 15 (1). doi:10.1038/s41598-025-01563-5. ISSN 2045-2322. PMC 12069583. PMID 40355523.
  12. ^ "ACSF3 acyl-CoA synthetase family member 3 [Homo sapiens (human)]". NCBI Gene. National Center for Biotechnology Information, U.S. National Library of Medicine. Retrieved 9 August 2025.
  13. ^ "Synthesis of Fatty Acids". The Medical Biochemistry Page. Retrieved 2025-09-08.
  14. ^ a b c d e f g Witkowski, Andrzej; Thweatt, Jennifer; Smith, Stuart (2011). "Mammalian ACSF3 Protein Is a Malonyl-CoA Synthetase That Supplies the Chain Extender Units for Mitochondrial Fatty Acid Synthesis". Journal of Biological Chemistry. 286 (39): 33729–33736. doi:10.1074/jbc.M111.291591. PMC 3190830. PMID 21846720.
  15. ^ a b c d e f g h Bowman, Caitlyn E.; Wolfgang, Michael J. (2019). "Role of the malonyl-CoA synthetase ACSF3 in mitochondrial metabolism". Advances in Biological Regulation. 71: 34–40. doi:10.1016/j.jbior.2018.09.002. PMC 6347522. PMID 30201289.
  16. ^ Watkins, Paul A.; Maiguel, Dony; Jia, Zhenzhen; Pevsner, Jonathan (December 2007). "Evidence for 26 distinct acyl-coenzyme A synthetase genes in the human genome". Journal of Lipid Research. 48 (12): 2736–2750. doi:10.1194/jlr.M700378-JLR200. PMID 17762044.
  17. ^ Prag, Hiran A.; Aksentijevic, Dunja; Dannhorn, Andreas; Giles, Abigail V.; Mulvey, John F.; Sauchanka, Olga; Du, Luping; Bates, Georgina; Reinhold, Johannes; Kula-Alwar, Duvaraka; Xu, Zhelong; Pellerin, Luc; Goodwin, Richard J. A.; Murphy, Michael P.; Krieg, Thomas (2022-09-02). "Ischemia-Selective Cardioprotection by Malonate for Ischemia/Reperfusion Injury". Circulation Research. 131 (6): 528–541. doi:10.1161/CIRCRESAHA.121.320717. ISSN 0009-7330. PMC 9426742. PMID 35959683.
  18. ^ Baumgartner, Matthias R; Hörster, Friederike; Dionisi-Vici, Carlo; Haliloglu, Goknur; Karall, Daniela; Chapman, Kimberly A; Huemer, Martina; Hochuli, Michel; Assoun, Murielle; Ballhausen, Diana; Burlina, Alberto; Fowler, Brian; Grünert, Sarah C; Grünewald, Stephanie; Honzik, Tomas (December 2014). "Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia". Orphanet Journal of Rare Diseases. 9 (1). doi:10.1186/s13023-014-0130-8. ISSN 1750-1172. PMC 4180313. PMID 25205257.
  19. ^ Pilevar, Zahra; Mousavi Khaneghah, Amin; Hosseini, Hedayat; Ranaei, Vahid (2020-07-31). "Propionic Acid: Method of Production, Current State and Perspectives". Food technology and biotechnology. 58 (2): 115–127. doi:10.17113/ftb.58.02.20.6356. PMC 7416123. PMID 32831564.
  20. ^ a b c Tejero, Joanne; Lazure, Felicia; Gomes, Ana P. (March 2024). "Methylmalonic acid in aging and disease". Trends in Endocrinology & Metabolism. 35 (3): 188–200. doi:10.1016/j.tem.2023.11.001. PMC 10939937. PMID 38030482.
  21. ^ Tillander, Veronika; Arvidsson Nordström, Elisabet; Reilly, Jenny; Strozyk, Malgorzata; Van Veldhoven, Paul P.; Hunt, Mary C.; Alexson, Stefan E. H. (March 2014). "Acyl-CoA thioesterase 9 (ACOT9) in mouse may provide a novel link between fatty acid and amino acid metabolism in mitochondria". Cellular and Molecular Life Sciences. 71 (5): 933–948. doi:10.1007/s00018-013-1422-1. ISSN 1420-682X. PMC 11114068. PMID 23864032.
  22. ^ Zhang, Yufeng; Wang, Jie; Yi, Chuanyou; Su, Yue; Yin, Zi; Zhang, Shuxian; Jin, Li; Stoneking, Mark; Yang, Jian; Wang, Ke; Huang, He; Li, Jin; Fan, Shaohua (June 2025). "An ancient regulatory variant of ACSF3 influences the coevolution of increased human height and basal metabolic rate via metabolic homeostasis". Cell Genomics. 5 (6) 100855. doi:10.1016/j.xgen.2025.100855. PMC 12230238. PMID 40403731.
  23. ^ Kölker, S.; Ahlmeyer, B.; Krieglstein, J.; Hoffmann, G. F. (2000). "Methylmalonic acid induces excitotoxic neuronal damage in vitro". Journal of Inherited Metabolic Disease. 23 (4): 355–358. doi:10.1023/A:1005631230455. PMID 10896293. S2CID 10374239.
  24. ^ a b Nowinski, Sara M.; Van Vranken, Jonathan G.; Dove, Katja K.; Rutter, Jared (October 2018). "Impact of Mitochondrial Fatty Acid Synthesis on Mitochondrial Biogenesis". Current Biology. 28 (20): R1212 – R1219. doi:10.1016/j.cub.2018.08.022. PMC 6258005. PMID 30352195.
  25. ^ Monteuuis, Geoffray; Suomi, Fumi; Kerätär, Juha M.; Masud, Ali J.; Kastaniotis, Alexander J. (2017-11-06). "A conserved mammalian mitochondrial isoform of acetyl-CoA carboxylase ACC1 provides the malonyl-CoA essential for mitochondrial biogenesis in tandem with ACSF3". Biochemical Journal. 474 (22): 3783–3797. doi:10.1042/bcj20170416. PMID 28986507.
  26. ^ a b c d e f Tucci, Sara (2020). "Brain metabolism and neurological symptoms in combined malonic and methylmalonic aciduria". Orphanet Journal of Rare Diseases. 15 (1) 27. doi:10.1186/s13023-020-1299-7. ISSN 1750-1172. PMC 6977288. PMID 31969167.
  27. ^ Nowinski, Sara M; Solmonson, Ashley; Rusin, Scott F; Maschek, J Alan; Bensard, Claire L; Fogarty, Sarah; Jeong, Mi-Young; Lettlova, Sandra; Berg, Jordan A; Morgan, Jeffrey T; Ouyang, Yeyun; Naylor, Bradley C; Paulo, Joao A; Funai, Katsuhiko; Cox, James E (2020-08-17). "Mitochondrial fatty acid synthesis coordinates oxidative metabolism in mammalian mitochondria". eLife. 9. doi:10.7554/eLife.58041. ISSN 2050-084X. PMC 7470841. PMID 32804083.
  28. ^ a b c d e Alatibi, Khaled; Sumser, Kathrin; Christopoulou, Maria Elpida; Hug, Martin J.; Tucci, Sara (March 2025). "Dysregulated mitochondrial fission and neurodegeneration proteomic signature in ACSF3-deficient cells". Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1870 (2) 159582. doi:10.1016/j.bbalip.2024.159582. PMID 39581258.
  29. ^ Tang, Jia Xin; Thompson, Kyle; Taylor, Robert W.; Oláhová, Monika (2020-05-28). "Mitochondrial OXPHOS Biogenesis: Co-Regulation of Protein Synthesis, Import, and Assembly Pathways". International Journal of Molecular Sciences. 21 (11) 3820. doi:10.3390/ijms21113820. ISSN 1422-0067. PMC 7312649. PMID 32481479.
  30. ^ a b Van Vranken, Jonathan G.; Nowinski, Sara M.; Clowers, Katie J.; Jeong, Mi-Young; Ouyang, Yeyun; Berg, Jordan A.; Gygi, Jeremy P.; Gygi, Steven P.; Winge, Dennis R.; Rutter, Jared (August 2018). "ACP Acylation Is an Acetyl-CoA-Dependent Modification Required for Electron Transport Chain Assembly". Molecular Cell. 71 (4): 567–580.e4. doi:10.1016/j.molcel.2018.06.039. PMC 6104058. PMID 30118679.
  31. ^ Masud, Ali J.; Kastaniotis, Alexander J.; Rahman, M. Tanvir; Autio, Kaija J.; Hiltunen, J. Kalervo (December 2019). "Mitochondrial acyl carrier protein (ACP) at the interface of metabolic state sensing and mitochondrial function". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1866 (12) 118540. doi:10.1016/j.bbamcr.2019.118540.
  32. ^ Hirschey, Matthew D.; Zhao, Yingming (September 2015). "Metabolic Regulation by Lysine Malonylation, Succinylation, and Glutarylation". Molecular & Cellular Proteomics. 14 (9): 2308–2315. doi:10.1074/mcp.R114.046664. PMC 4563717. PMID 25717114.
  33. ^ Zou, Lu; Yang, Yanyan; Wang, Zhibin; Fu, Xiuxiu; He, Xiangqin; Song, Jiayi; Li, Tianxiang; Ma, Huibo; Yu, Tao (2023). "Lysine Malonylation and Its Links to Metabolism and Diseases". Aging and disease. 14 (1): 84–98. doi:10.14336/AD.2022.0711. ISSN 2152-5250. PMC 9937698. PMID 36818560.
  34. ^ a b Le Questel, Enora; Besnard, Charlène; Atger, Florian; Foucher, Yolène; Tollec, Alwéna; Pakulska, Victoria; Rodrigues Oliveira, Arsênio; Clotteau, Chloé; Gourdel, Mathilde (2024-09-06), Diurnal regulation of Acyl-CoA synthetase 3 (ACSF3) underlies daily mitochondrial lysine-malonylation and hepatic metabolism, doi:10.1101/2024.09.03.607283
  35. ^ Lombard, David B.; Zhao, Yingming (June 2017). "ACSF3 and Mal(onate)-Adapted Mitochondria". Cell Chemical Biology. 24 (6): 649–650. doi:10.1016/j.chembiol.2017.06.004. PMID 28644952.
  36. ^ Hamilton, James A. (November 2007). "New insights into the roles of proteins and lipids in membrane transport of fatty acids". Prostaglandins, Leukotrienes and Essential Fatty Acids. 77 (5–6): 355–361. doi:10.1016/j.plefa.2007.10.020. PMID 18032007.
  37. ^ a b Wongkittichote, Parith; Ah Mew, Nicholas; Chapman, Kimberly A. (December 2017). "Propionyl-CoA carboxylase – A review". Molecular Genetics and Metabolism. 122 (4): 145–152. doi:10.1016/j.ymgme.2017.10.002. PMC 5725275. PMID 29033250.
  38. ^ Lancaster, Makayla S.; Graham, Brett H. (2023-06-27). "Succinyl-CoA Synthetase Dysfunction as a Mechanism of Mitochondrial Encephalomyopathy: More than Just an Oxidative Energy Deficit". International Journal of Molecular Sciences. 24 (13) 10725. doi:10.3390/ijms241310725. ISSN 1422-0067. PMC 10342173. PMID 37445899.
  39. ^ a b c Head, PamelaSara E.; Myung, Sangho; Chen, Yong; Schneller, Jessica L.; Wang, Cindy; Duncan, Nicholas; Hoffman, Pauline; Chang, David; Gebremariam, Abigael; Gucek, Marjan; Manoli, Irini; Venditti, Charles P. (2022-05-25). "Aberrant methylmalonylation underlies methylmalonic acidemia and is attenuated by an engineered sirtuin". Science Translational Medicine. 14 (646). doi:10.1126/scitranslmed.abn4772. ISSN 1946-6234. PMC 10468269. PMID 35613279.
  40. ^ Ngo, Jennifer; Choi, Dong Wook; Stanley, Illana A; Stiles, Linsey; Molina, Anthony J A; Chen, Pei‐Hsuan; Lako, Ana; Sung, Isabelle Chiao Han; Goswami, Rishov; Kim, Min‐young; Miller, Nathanael; Baghdasarian, Siyouneh; Kim‐Vasquez, Doyeon; Jones, Anthony E; Roach, Brett (June 2023). "Mitochondrial morphology controls fatty acid utilization by changing CPT1 sensitivity to malonyl‐CoA". The EMBO Journal. 42 (11). doi:10.15252/embj.2022111901. ISSN 0261-4189. PMC 10233380. PMID 36917141.
  41. ^ Horn, Adam; Jaiswal, Jyoti K. (2020-10-30). "Splitting up to heal: mitochondrial shape regulates signaling for focal membrane repair". Biochemical Society Transactions. 48 (5): 1995–2002. doi:10.1042/BST20200120. ISSN 0300-5127. PMC 8090898. PMID 32985660.
  42. ^ Paradies, Giuseppe; Paradies, Valeria; Ruggiero, Francesca M.; Petrosillo, Giuseppe (2014-04-20). "Cardiolipin and Mitochondrial Function in Health and Disease". Antioxidants & Redox Signaling. 20 (12): 1925–1953. doi:10.1089/ars.2013.5280. ISSN 1523-0864. PMID 24094094.
  43. ^ a b Held, Patrice K.; Singh, Emily; Scott Schwoerer, Jessica (2022-02-07). "Screening for Methylmalonic and Propionic Acidemia: Clinical Outcomes and Follow-Up Recommendations". International Journal of Neonatal Screening. 8 (1): 13. doi:10.3390/ijns8010013. ISSN 2409-515X. PMC 8883915. PMID 35225935.
  44. ^ a b Schnabel, Elena; Kölker, Stefan; Gleich, Florian; Feyh, Patrik; Hörster, Friederike; Haas, Dorothea; Fang-Hoffmann, Junmin; Morath, Marina; Gramer, Gwendolyn; Röschinger, Wulf; Garbade, Sven F.; Hoffmann, Georg F.; Okun, Jürgen G.; Mütze, Ulrike (2023-07-28). "Combined Newborn Screening Allows Comprehensive Identification also of Attenuated Phenotypes for Methylmalonic Acidurias and Homocystinuria". Nutrients. 15 (15): 3355. doi:10.3390/nu15153355. ISSN 2072-6643. PMC 10420807. PMID 37571294.
  45. ^ a b Pajares, Sonia; Arranz, Jose Antonio; Ormazabal, Aida; Del Toro, Mireia; García-Cazorla, Ángeles; Navarro-Sastre, Aleix; López, Rosa María; Meavilla, Silvia María; de los Santos, Mariela Mercedes; García-Volpe, Camila; de Aledo-Castillo, Jose Manuel González; Argudo, Ana; Marín, Jose Luís; Carnicer, Clara; Artuch, Rafael (2021-04-30). "Implementation of second-tier tests in newborn screening for the detection of vitamin B12 related acquired and genetic disorders: results on 258,637 newborns". Orphanet Journal of Rare Diseases. 16 (1): 195. doi:10.1186/s13023-021-01784-7. ISSN 1750-1172. PMC 8086297. PMID 33931066.
  46. ^ a b c d Manoli I, Sloan JL, Venditti CP. Isolated Methylmalonic Acidemia. 2005 Aug 16 [Updated 2022 Sep 8]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1231/
  47. ^ a b c d e Gregg, A. R.; Warman, A. W.; Thorburn, D. R.; O'Brien, W. E. (1998). "Combined malonic and methylmalonic aciduria with normal malonyl-coenzyme A decarboxylase activity: A case supporting multiple aetiologies". Journal of Inherited Metabolic Disease. 21 (4): 382–390. doi:10.1023/A:1005302607897. PMID 9700595. S2CID 20212973.
  48. ^ "Targeted Genes and Methodology Details for Methylmalonic Aciduria Gene Panel". Mayo Clinic Laboratories. Retrieved 2024-05-16.
  49. ^ Gabriel, Marie Cosette; Rice, Stephanie M.; Sloan, Jennifer L.; Mossayebi, Matthew H.; Venditti, Charles P.; Al-Kouatly, Huda B. (2021). "Considerations of expanded carrier screening: Lessons learned from combined malonic and methylmalonic aciduria". Molecular Genetics & Genomic Medicine. 9 (4) e1621. doi:10.1002/mgg3.1621. ISSN 2324-9269. PMC 8123733. PMID 33625768.
  50. ^ Adeva‐Andany, María M.; Calvo‐Castro, Isabel; Fernández‐Fernández, Carlos; Donapetry‐García, Cristóbal; Pedre‐Piñeiro, Ana María (August 2017). "Significance of l ‐carnitine for human health". IUBMB Life. 69 (8): 578–594. doi:10.1002/iub.1646. ISSN 1521-6543. PMID 28653367.
  51. ^ Martini, Paolo G.V.; Guey, Lin T. (2019). "A New Era for Rare Genetic Diseases: Messenger RNA Therapy". Human Gene Therapy. 30 (10): 1180–1189. doi:10.1089/hum.2019.090. ISSN 1043-0342. PMID 31179759. S2CID 182947527.
  52. ^ "A Clinical Trial of a Treatment for Patients with Methylmalonic Acidemia (MMA)". trials.modernatx.com. Retrieved 2022-06-20.
  53. ^ "COMBINED MALONIC AND METHYLMALONIC ACIDURIA; CMAMMA". OMIM. Retrieved 2024-04-20.
  54. ^ "Combined malonic and methylmalonic acidemia". National Library of Medicine. Retrieved 2024-04-20.
  55. ^ Brown, G. K.; Scholem, R. D.; Bankier, A.; Danks, D. M. (1984). "Malonyl coenzyme a decarboxylase deficiency". Journal of Inherited Metabolic Disease. 7 (1): 21–26. doi:10.1007/BF01805615. ISSN 0141-8955. PMID 6145813. S2CID 33045087.
  56. ^ Ozand, P.T.; Nyhan, W.L.; Al Aqeel, A.; Christodoulou, J. (1994). "Malonic aciduria". Brain and Development. 16: 7–11. doi:10.1016/0387-7604(94)90091-4. PMID 7537025. S2CID 4768844.
  57. ^ "Newborn blood screening" (PDF). Ministère de la Santé et des Services sociaux (MSSS) du Québec. Retrieved 2025-08-12.
[edit]